These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31853652)

  • 21. Predictors of cognitive impairment in newly diagnosed Parkinson's disease with normal cognition at baseline: A 5-year cohort study.
    Chen J; Zhao D; Wang Q; Chen J; Bai C; Li Y; Guo X; Chen B; Zhang L; Yuan J
    Front Aging Neurosci; 2023; 15():1142558. PubMed ID: 36926634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive function in the early phase of Parkinson's disease, a five-year follow-up.
    Domellöf ME; Ekman U; Forsgren L; Elgh E
    Acta Neurol Scand; 2015 Aug; 132(2):79-88. PubMed ID: 25644230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mild Cognitive Impairment in Parkinson's Disease-What Is It?
    Weil RS; Costantini AA; Schrag AE
    Curr Neurol Neurosci Rep; 2018 Mar; 18(4):17. PubMed ID: 29525906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Senescence and Inflammatory Markers for Predicting Clinical Progression in Parkinson's Disease: The ICICLE-PD Study.
    Martin-Ruiz C; Williams-Gray CH; Yarnall AJ; Boucher JJ; Lawson RA; Wijeyekoon RS; Barker RA; Kolenda C; Parker C; Burn DJ; Von Zglinicki T; Saretzki G
    J Parkinsons Dis; 2020; 10(1):193-206. PubMed ID: 31868677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
    Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB
    Brain; 2017 Jul; 140(7):1959-1976. PubMed ID: 28549077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subjective cognitive decline predicts future deterioration in cognitively normal patients with Parkinson's disease.
    Hong JY; Sunwoo MK; Chung SJ; Ham JH; Lee JE; Sohn YH; Lee PH
    Neurobiol Aging; 2014 Jul; 35(7):1739-43. PubMed ID: 24507441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients.
    Pellecchia MT; Santangelo G; Picillo M; Pivonello R; Longo K; Pivonello C; Vitale C; Amboni M; De Rosa A; Moccia M; Erro R; De Michele G; Santoro L; Colao A; Barone P
    J Neurol; 2013 Feb; 260(2):438-44. PubMed ID: 22911513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contribution of language studies to the understanding of cognitive impairment and its progression over time in Parkinson's disease.
    Auclair-Ouellet N; Lieberman P; Monchi O
    Neurosci Biobehav Rev; 2017 Sep; 80():657-672. PubMed ID: 28782623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).
    Mollenhauer B; Zimmermann J; Sixel-Döring F; Focke NK; Wicke T; Ebentheuer J; Schaumburg M; Lang E; Friede T; Trenkwalder C;
    Mov Disord; 2019 Jan; 34(1):67-77. PubMed ID: 30468694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Greater intraindividual variability in neuropsychological performance predicts cognitive impairment in de novo Parkinson's disease.
    Jones JD; Burroughs M; Apodaca M; Bunch J
    Neuropsychology; 2020 Jan; 34(1):24-30. PubMed ID: 31219297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dementia and cognitive impairment in patients with Parkinson's disease from India: a 7-year prospective study.
    Sanyal J; Banerjee TK; Rao VR
    Am J Alzheimers Dis Other Demen; 2014 Nov; 29(7):630-6. PubMed ID: 24771763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.
    Tropea TF; Xie SX; Rick J; Chahine LM; Dahodwala N; Doshi J; Davatzikos C; Shaw LM; Van Deerlin V; Trojanowski JQ; Weintraub D; Chen-Plotkin AS
    Mov Disord; 2018 Feb; 33(2):289-297. PubMed ID: 29168904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mild cognitive impairment in Parkinson's disease: Diagnosis and progression to dementia.
    Galtier I; Nieto A; Lorenzo JN; Barroso J
    J Clin Exp Neuropsychol; 2016; 38(1):40-50. PubMed ID: 26602176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive impairment in Parkinson's disease is multifactorial: A neuropsychological study.
    Smith CR; Cullen B; Sheridan MP; Cavanagh J; Grosset KA; Grosset DG
    Acta Neurol Scand; 2020 Jun; 141(6):500-508. PubMed ID: 32002988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The interlocking finger test in patients with Parkinson's disease and healthy subjects.
    Souza CP; Oliveira GN; Foss MP; Tumas V
    J Clin Neurosci; 2016 Jul; 29():145-8. PubMed ID: 26960261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastrointestinal symptoms are predictive of trajectories of cognitive functioning in de novo Parkinson's disease.
    Jones JD; Rahmani E; Garcia E; Jacobs JP
    Parkinsonism Relat Disord; 2020 Mar; 72():7-12. PubMed ID: 32058266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropsychological predictors of patient-reported cognitive decline after deep brain stimulation in Parkinson's disease.
    Mills KA; Donohue K; Swaminathan A; Leoutsakos JM; Smith G; Brandt J
    J Clin Exp Neuropsychol; 2019 Apr; 41(3):219-228. PubMed ID: 30296894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Odor selectivity of hyposmia and cognitive impairment in patients with Parkinson's disease.
    Mao CJ; Wang F; Chen JP; Yang YP; Chen J; Huang JY; Liu CF
    Clin Interv Aging; 2017; 12():1637-1644. PubMed ID: 29070942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease.
    Filippi M; Canu E; Donzuso G; Stojkovic T; Basaia S; Stankovic I; Tomic A; Markovic V; Petrovic I; Stefanova E; Kostic VS; Agosta F
    Mov Disord; 2020 Nov; 35(11):1987-1998. PubMed ID: 32886420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.